• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

肾上腺皮质癌术后应用米托坦治疗有效性的Meta分析

The therapeutic efficacy of postoperative adjuvant mitotane therapy in adrenocortical carcinoma, a Meta-analysis

摘要:

目的:探讨肾上腺皮质癌(ACC)术后应用米托坦治疗的有效性。方法:对PubMed、EMBASE、Web of Science、Cochrane Library数据库行系统文献检索,检索时限自建库至2023年10月。检索词包括"mitotane""adrenocortical carcinoma或其同义词"。纳入标准:研究中比较了ACC术后是否应用米托坦的相应预后情况[(总生存期(OS)和/或无复发生存期(RFS)];多因素Cox回归分析中报告调整后的风险比(HR)。排除标准:患者有远处转移、ACC的显微镜下残留(RI)切除、术前或术后辅助化疗。提取符合条件的研究数据,包括辅助米托坦的治疗浓度、治疗持续时间、肿瘤分期等。比较ACC术后是否应用米托坦对OS和RFS的影响,根据米托坦是否达到有效浓度或足够时间,以及肿瘤分期≤T 3期对RFS进行亚组分析。 结果:本研究最终纳入15篇研究,包括2 084例ACC患者,其中术后应用米托坦991例。肿瘤分期≤T 3期753例。术后应用米托坦组的OS( HR=0.45,95% CI 0.34~0.58, I2=0, P=0.79)和RFS( HR=0.65,95% CI 0.51~0.83, I2=76%, P<0.01)明显优于未应用米托坦组。亚组分析结果显示,相比于术后应用米托坦未达到有效浓度或足够时间组,达到有效浓度或足够时间组[中位随访时间<45个月亚组( HR=0.59,95% CI 0.44~0.79, I2=0, P=0.38);中位随访时间≥45个月亚组( HR=0.93,95% CI 0.90~0.96, I2=0, P=1.00)]的RFS更优。与T 4期相比,≤T 3期ACC患者( HR=0.61,95% CI 0.47~0.79, I2=0, P=0.62)的RFS更优。 结论:ACC术后应用米托坦能延长患者的OS和RFS;尤其对于应用米托坦达到有效浓度或足够时间的患者,以及≤T 3期的患者,其延长RFS的效果更稳定。

更多
abstracts:

Objective:Object To evaluate the therapeutic effectiveness of postoperative adjuvant mitotane therapy in the context of adrenocortical carcinoma (ACC) by using a meta-analysis methodology.Methods:A comprehensive literature review was conducted by systematically searching the PubMed, EMBASE, Web of Science, and Cochrane Library databases. The search spanned from the establishment of each database to October 2023. Search terms, "mitotane", "adrenocortical carcinoma" or synonyms. Inclusion criteria, Studies comparing outcomes (overall survival (OS) and/or recurrence-free survival (RFS)) in ACC patients with or without mitotane, reporting adjusted hazard ratios (HR) in multivariate Cox regression. Exclusion criteria, Patients with distant metastases, RI(Microscopic residual tumor) rection of ACC, or adjuvant chemotherapy. Data extracted on mitotane treatment concentration, duration, and tumor stage. A meta-analysis was conducted utilizing R4.2.2 software to assess the impact of ACC on OS or RFS through the calculation of HR and 95% confidence intervals (CI). Subgroup analysis of RFS was conducted based on the use of mitotane to reach effective levels or adequate duration, as well as tumor stage ≤T 3. Results:A meta-analysis was conducted, including a total of 15 studies and involving 2084 patients with ACC. Of these patients, 991 received post-surgical treatment with mitotane, while 753 had ACC classified as stages ≤T 3. The results showed that adjuvant mitotane therapy in the ACC group after surgery led to significantly improved OS ( HR=0.45, 95% CI 0.34-0.58, I2=0, P=0.79) and RFS ( HR=0.65, 95% CI 0.51-0.83, I2=76%, P<0.01) compared to non-adjuvant mitotane therapy. Subgroup analysis further revealed that patients with effective mitotane concentration or sufficient time after surgery[Subgroup a(Median follow-up duration < 45 months): HR=0.59, 95% CI 0.44-0.79, I2=0, P=0.38; Subgroup b(Median follow-up duration ≥ 45 months): HR=0.93, 95% CI 0.90-0.96, I2=0, P=1.00 ]and with ≤T 3 stage ACC ( HR=0.61, 95% CI 0.47-0.79, I2=0, P=0.62)had better RFS compared to those who did not achieve the requisite mitotane concentration or postoperative interval, as well as patients with stage T 4 ACC. Conclusions:The administration of adjuvant mitotane therapy following ACC resection has been shown to significantly extend patients' OS and RFS, particularly when the therapy achieves optimal concentration or is administered for an adequate duration. Furthermore, in patients with ACC classified as stage ≤T 3, the effect of adjuvant mitotane therapy on prolonging RFS appears to be more consistent and reliable.

More
作者: 肖泽涛 [1] 肖礼松 [1] 唐金矿 [1] 徐从杰 [1] 王阳 [1] 周家权 [1]
期刊: 《中华泌尿外科杂志》2024年45卷4期 306-313页 ISTICPKUCSCD
栏目名称: 肾上腺源性皮质醇增多症的外科治疗
DOI: 10.3760/cma.j.cn112330-20240130-00049
发布时间: 2024-07-30
  • 浏览:0
  • 下载:0

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
manbet官网登录 小程序
new翻译 充值 订阅 收藏 移动端

官方微信

manbet官网登录 小程序

使用
帮助
Alternate Text
调查问卷